Company Profile
MedRx Co., Ltd, a pharmaceutical formulation development company provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS) microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin.
Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain. Its portfolio also includes MRX-4TZT, which is in a Phase II trial for spastic paralysis, Alto-101, which is in a Phase II trial for schizophrenia, MRX-9FLT, which is in a Phase I trial for moderate to severe pain, and MRX-6LDT, which is in a drug formulation development stage for chronic pain. Incorporated in 2002, MedRx is headquartered in Higashikagawa, Japan.